MedPath

Comparison of Brovavir Versus Acyclovir in the Treatment of Herpes in HIV-Infected Patients

Phase 2
Completed
Conditions
HIV Infections
Chickenpox
Registration Number
NCT00000953
Lead Sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
Brief Summary

To compare the efficacy of oral sorivudine (brovavir) and oral acyclovir for the treatment of localized herpes zoster in HIV-infected patients.

HIV-infected patients are at high risk for herpesvirus infections, including varicella-zoster virus ( VZV ) infections, also called shingles. Acyclovir, an approved drug, is widely used to treat VZV infections in the HIV population. Since no data from controlled studies are available to define the role of antiviral therapy for VZV infections in HIV-infected patients, a study is needed to test the relative efficacy of brovavir, an experimental antiviral drug, versus that of acyclovir.

Detailed Description

HIV-infected patients are at high risk for herpesvirus infections, including varicella-zoster virus ( VZV ) infections, also called shingles. Acyclovir, an approved drug, is widely used to treat VZV infections in the HIV population. Since no data from controlled studies are available to define the role of antiviral therapy for VZV infections in HIV-infected patients, a study is needed to test the relative efficacy of brovavir, an experimental antiviral drug, versus that of acyclovir.

One hundred-eighty patients are randomized to receive either brovavir or acyclovir as follows: brovavir or its matching placebo once daily and acyclovir or its matching placebo five times daily. Treatment continues for 10 days. Entry into the study must occur within 72 hours of lesion development. Patients are followed in person daily or at regular intervals during study drug administration and on days 14, 21, and 28, and then monthly by telephone for 11 months thereafter.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
180
Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

Study Type
INTERVENTIONAL
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (44)

Univ of Alabama at Birmingham

🇺🇸

Birmingham, Alabama, United States

Univ of Southern California / LA County USC Med Ctr

🇺🇸

Los Angeles, California, United States

UCLA Med Ctr

🇺🇸

Los Angeles, California, United States

Veterans Administration Med Ctr

🇺🇸

Martinez, California, United States

Infectious Disease Med Group

🇺🇸

Oakland, California, United States

San Diego Naval Hosp

🇺🇸

San Diego, California, United States

Mount Zion Med Ctr

🇺🇸

San Francisco, California, United States

Univ of Colorado Health Sciences Ctr

🇺🇸

Denver, Colorado, United States

George Washington Univ Med Ctr

🇺🇸

Washington, District of Columbia, United States

Veterans Administration Med Ctr / Community AIDS Program

🇺🇸

Washington, District of Columbia, United States

Scroll for more (34 remaining)
Univ of Alabama at Birmingham
🇺🇸Birmingham, Alabama, United States

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.